Patients receiving a stable oral dosage of carbamazepine were switched to an intravenous ( IV ) carbamazepine formulation solubilized in a cyclodextrin matrix ( at a @ % dosage conversion ) for either a @ - or a @-min infusion every @ h for up to @ days and then switched back .